Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2214-109X(25)00006-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines.
J Immunol
February 2025
Vaccine Research Institute, Université Paris-Est Créteil, Créteil, France.
The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara (MVA) Bavarian Nordic or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody responders was higher among MPXV-infected individuals than MVA vaccinees.
View Article and Find Full Text PDFExploring the Application of Target Trial Emulation in Vaccine Evaluation: Scoping Review.
Am J Epidemiol
March 2025
Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Target trial emulation (TTE) has gained popularity in evaluating treatments and health interventions. Its application to infectious disease outcomes requires careful consideration, as infectious disease transmission violates the assumption of no interference. Thus, we conducted a scoping review to understand how TTE approaches have been applied to vaccine evaluation.
View Article and Find Full Text PDFModeling the Impact of Vaccine Dose Prioritization Strategies During the 2022 Mpox Outbreak.
Am J Epidemiol
March 2025
CDC, National Center for HIV, Hepatitis, STD, and Tuberculosis Prevention, Division of STD Prevention.
Early in the 2022 mpox outbreak, the U.S. recommendation was to administer two doses of the JYNNEOS® vaccine 4 weeks apart.
View Article and Find Full Text PDFLyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Hum Vaccin Immunother
December 2025
Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.
The World Health Organization (WHO) has recently declared another global health emergency due to the rapidly spreading monkeypox (Mpox) outbreak in numerous African countries. To address the unmet need to contain the outbreak using the existing vaccines, this study developed a lyophilization process for an effective, scalable and affordable Mpox mRNA-LNP vaccine candidate to address the global health crisis. A comprehensive evaluation and optimization of the vaccine formulation (the type/concentration of cryoprotectants, the type/concentration of buffer system, as well as the mRNA concentration and reconstitution solvent) and the freeze-drying process parameters (freezing method, temperature, cooling rate and primary/secondary drying conditions) were conducted.
View Article and Find Full Text PDFScientometric Study of Mpox and Vaccine Research: Dynamics, Emerging Patterns, and Networking.
Health Sci Rep
March 2025
Vicerrectorado de Investigación Universidad San Ignacio de Loyola Lima Peru.
Background And Aim: Mpox (Monkeypox) is a zoonotic disease transmitted through contact with infected animals or humans. Recent research focuses on epidemiology, transmission, and vaccine development to combat its resurgence. This bibliometric study analyzed the dynamics, emerging patterns, and networks of mpox and vaccine research from 2019 to 2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!